Form 4: Director Antonio Pera Receives ANIP Stock Award

Director Antonio R. Pera acquired 4,357 shares of ANI Pharmaceuticals, Inc. common stock via a restricted stock award.

Summary

• Director Antonio R. Pera was granted 4,357 shares of common stock in ANI Pharmaceuticals, Inc. (ANIP).
• The transaction occurred on May 21, 2026.
• The shares were acquired at a price of $0 per share as part of a restricted stock award.
• Following this transaction, the director's total beneficial ownership increased to 27,017 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral in terms of immediate market impact.

Positives

• Alignment of director interests with shareholders through equity-based compensation.
• Increase in total beneficial ownership by a member of the board.

Negatives

• None identified.

Risks

• The restricted stock award is subject to a vesting schedule, meaning the director does not have immediate full ownership until the vesting date.

Future Outlook

The restricted stock award is scheduled to vest in full on May 21, 2027.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practices in the pharmaceutical industry to ensure long-term alignment between board members and company performance.

Comparison to Industry Standards

• The use of restricted stock awards for director compensation is consistent with standard practices among mid-cap pharmaceutical companies.
• The vesting period of one year is a common retention and incentive structure in the sector.

Stakeholder Impact

• Shareholders: Minimal impact, as this is a standard equity grant to a director.

Next Steps

• Vesting of the 4,357 shares on May 21, 2027.

Key Dates

Keywords

ANIP, ANI Pharmaceuticals, Form 4, Insider Trading, Director Compensation, Equity Award